Clinical Trial Update: Phase II Study of TKI258 in Advanced Urothelial Carcinoma [Phase 2]

View source ↗

Summary

Phase II study update of TKI258 in advanced urothelial carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Cancer

Drugs mentioned

• TKI258

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Urothelial Cancer | Phase 2 | Status: COMPLETED